These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38709312)

  • 21. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
    Bhave P; Pallan L; Long GV; Menzies AM; Atkinson V; Cohen JV; Sullivan RJ; Chiarion-Sileni V; Nyakas M; Kahler K; Hauschild A; Plummer R; Trojaniello C; Ascierto PA; Zimmer L; Schadendorf D; Allayous C; Lebbe C; Maurichi A; Santinami M; Roy S; Robert C; Lesimple T; Patel S; Versluis JM; Blank CU; Khattak A; Van der Westhuizen A; Carlino MS; Shackleton M; Haydon A
    Br J Cancer; 2021 Feb; 124(3):574-580. PubMed ID: 33087895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review.
    Lai-Kwon J; Inderjeeth AJ; Lisy K; Sandhu S; Rutherford C; Jefford M
    Eur J Cancer; 2023 May; 184():83-105. PubMed ID: 36907021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
    Pokorny R; McPherson JP; Haaland B; Grossmann KF; Luckett C; Voorhies BN; Sageser DS; Wallentine J; Tolman Z; Hu-Lieskovan S; Swami U
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel.
    Grote C; Bohne AS; Blome C; Kähler KC
    J Cancer Res Clin Oncol; 2024 Oct; 150(10):454. PubMed ID: 39387946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series.
    Konishi K; Okamoto M; Tokumitsu R; Yano M; Nasu K; Kobayashi E
    Med Mol Morphol; 2024 Jun; 57(2):83-90. PubMed ID: 38289480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
    Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
    J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-reported outcomes and experiences from a prospective cohort study of older patients with cancer on checkpoint inhibitors: The ELDERS study.
    Gomes F; Khatoon B; Sawyer C; Punnett G; Farrington N; Yorke J
    J Geriatr Oncol; 2024 Jun; 15(5):101777. PubMed ID: 38704912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
    Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
    Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
    Woo TE; Stukalin I; Ding PQ; Goutam S; Sander M; Ewanchuk B; Cheung WY; Heng DYC; Cheng T
    Curr Oncol; 2023 Sep; 30(10):8936-8947. PubMed ID: 37887546
    [No Abstract]   [Full Text] [Related]  

  • 34. From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.
    Kamminga NCW; van der Veldt AAM; Wakkee M; van den Berge FR; van der Beek LAA; Joosen MCW; Joosse A; de Joode K; Nijsten TEC; Lugtenberg M
    BMC Cancer; 2024 May; 24(1):662. PubMed ID: 38816701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term immune-related adverse events after discontinuation of immunotherapy.
    Horisberger K; Portenkirchner C; Rickenbacher A; Biedermann L; Gubler C; Turina M
    Immunotherapy; 2021 Jun; 13(9):735-740. PubMed ID: 33882697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoassay Interference on Thyroid Function Tests During Treatment with Nivolumab.
    Paragliola RM; Corsello A; Papi G; Melfa E; Urbani A; Pontecorvi A; Corsello SM; Carrozza C
    Thyroid; 2020 Jul; 30(7):1091-1094. PubMed ID: 32122271
    [No Abstract]   [Full Text] [Related]  

  • 38. Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
    Weber J; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Di Giacomo AM; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Long GV; Lobo M; Askelson M; Ascierto PA; Larkin J
    J Clin Oncol; 2024 Nov; 42(31):3702-3712. PubMed ID: 39102624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
    Dalle S; Mortier L; Corrie P; Lotem M; Board R; Arance AM; Meiss F; Terheyden P; Gutzmer R; Buysse B; Oh K; Brokaw J; Le TK; Mathias SD; Scotto J; Lord-Bessen J; Moshyk A; Kotapati S; Middleton MR
    BMC Cancer; 2021 May; 21(1):642. PubMed ID: 34051732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
    Fukumoto T; Horita N
    Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.